A Phase 2 interventional study of Piperacillin Sodium and Tazobactam Sodium for Injection (Bangda®) and Piperacillin Sodium and Tazobactam Sodium for Injection (Bangda®) in PD Target Attainment Rate, Pneumonia and Elderly (People Aged 65 or More), sponsored by Shandong University. Recruiting at 1 site in China. Open to participants aged 65 Years to 110 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Shandong University · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 142 studies in Pneumonia with a site in China — 44 open to participants now, 48 under way, 2 of them phase 3. Pneumonia · China.
Among the 142 studies in Pneumonia with a site in China, this one is the 57th largest by planned enrollment of the 94 interventional ones that give a count, is one of 13 that started in 2026, is one of 8 in phase 2, reaches primary completion later than 37 of the 47 other live ones, and was the 139th registered.
1,569 studies on the registry are indexed under Pneumonia; 267 are open to participants now.
Browse Pneumonia studies →44 of the 142 studies in Pneumonia with a site in China are open now. Recruiting first, the newest first:
Beijing Continent Pharmaceutical Co, Ltd. · Sites in China
Ages 18–75
Zhongnan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18–80
Chongqing Medical University · Sites in China
Ages 18+
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 159 Pneumonia studies recruiting now, 84 (53%) set no upper age limit and 48 (30%) stop at 75 or younger; 40 take children under 18; 23 take healthy volunteers.
This study: 65 Years to 110 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
142 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 17 · Phase 3 21 · Phase 4 14
First in 2003; this study’s year is marked. 13 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 118 is close to the median of 128 across 978 interventional studies indexed under Pneumonia.
Median enrollment 154 across the 94 interventional studies, 350 across the 48 observational. Of the 51 that completed or were terminated, 3 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 142 have an industry lead sponsor. The 10 most frequent:
Shandong University is the lead sponsor of 295 studies on the registry; 63 are open to participants now.
Shandong University has 2 studies filed under Pneumonia — fewer than ten, so there is no comparison to draw.
11 of the studies in Pneumonia with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07388680Phase 3Beijing Continent Pharmaceutical Co, Ltd.Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune Pneumonia | 2026-12-30 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT07461714Guangzhou Medical UniversityAI-Driven Accurate Diagnosis of Pathogens in Severe Pneumonia | 2026-12-31 |
| NCT02738645Beijing Chao Yang HospitalA Clinical Cohort Study of Pneumonia in Respiratory Intensive Care Unit | 2026-12-31 |
| NCT07311343Beijing Tiantan HospitalOral Hygiene and Prophylactic Antibiotics to Prevent Intracerebral Hemorrhage Associated Pneumonia | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 142 studies in Pneumonia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study tests a new way to give an antibiotic to older adults with pneumonia. Pneumonia is a lung infection.
Piperacillin-tazobactam is an antibiotic. Doctors often use it to treat pneumonia in older adults. Right now, doctors usually give this drug every 8 hours. They let it drip into the vein over 3 hours.
But early research suggests a different schedule may work better. This study will test giving the drug every 6 hours. The drip will last 4 hours. Researchers think this may help the drug fight germs better.
The study will compare the usual schedule with the new schedule. Participants will join one of two groups. One group will get the usual schedule. The other group will get the new schedule.
Researchers will check how well the drug works. They will also watch for side effects. They want to find the safest and most helpful way to give this drug.
Adults aged 65 and older with community-acquired pneumonia can join. Community-acquired pneumonia is a lung infection that starts outside of a hospital.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Onset in the community setting;
At least one of the following clinical manifestations:
New-onset cough, sputum production, or worsening of pre-existing respiratory symptoms, with or without purulent sputum, chest pain, dyspnea, or hemoptysis; Fever; Signs of pulmonary consolidation and/or moist rales; Peripheral white blood cell count > 10×10⁹/L or \< 4×10⁹/L, with or without left shift; Chest imaging showing new patchy infiltrates, lobar/segmental consolidation, ground-glass opacities, or interstitial changes, with or without pleural effusion.
For patients aged ≥ 65 years with a body temperature \< 38°C, the presence of clear clinical signs of pneumonia and abnormal chest X-ray findings will also be considered meeting the inclusion criteria.
Comorbidities such as chronic cardiopulmonary disease, diabetes mellitus, renal failure, etc.; Use of broad-spectrum antibiotics within the past 3 months; History of repeated hospitalizations or residence in a long-term care facility;
Exclusion Criteria:
Post-randomization exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Piperacillin Sodium and Tazobactam Sodium for Injection (Bangda®)
Other: Piperacillin Sodium and Tazobactam Sodium for Injection (Bangda®)
Control arm (guideline-based conventional dosing): Piperacillin Sodium and Tazobactam Sodium for Injection (Bangda®) 4500 mg administered as a 3-hour intravenous infusion every 8 hours (q8h), for a total treatment course of 5-14 days.
Intervention arm (model-guided optimized dosing): Piperacillin Sodium and Tazobactam Sodium for Injection (Bangda®) 4500 mg administered as a 4-hour intravenous infusion every 6 hours (q6h), for a total treatment course of 5-14 days. This arm adopts increased dosing frequency and prolonged infusion duration compared with the control arm.
The proportion of patients achieving the predefined pharmacodynamic (PD) target.
Time frame: up to 1 month
Clinical improvement rate after 3 days of empiric therapy
Time frame: Day 3
Length of hospital stay
Time frame: through hospital discharge, an average of 2 weeks
Treatment success rate
Time frame: through hospital discharge, an average of 4 weeks
Adverse event (AE) incidence rate
Time frame: through end of study-drug treatment, an average of 7 days
Plan to share: No — Individual participant data (IPD) will not be shared due to patient privacy and confidentiality regulations, and the lack of specific informed consent for public data sharing.
Started Jul 2026 (actual). Primary completion is estimated for May 2027, 10 months after the start.
Of 40 non-industry phase 2 interventional studies under Pneumonia, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 28. This study's planned 10 months is close to that.
Counting every sponsor, half of 65 studies reached it within 14 months; a quarter within 7 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.